Olbromski Piotr Józef, Pawlik Piotr, Bogacz Anna, Sajdak Stefan
Clinic of Operational Gynecology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland.
Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland.
J Clin Med. 2022 Jul 4;11(13):3888. doi: 10.3390/jcm11133888.
Ovarian cancer is a common cause of death among women worldwide. The current diagnostic and prognostic procedures available for the treatment of ovarian cancer are either not specific or are very expensive. Gene expression profiling has proved to be a very effective tool in the exploration of new molecular markers in patients with ovarian cancer, although the link between such markers and patient survival and clinical outcomes is still elusive. We are looking for genes that may function in the development and progression of ovarian cancer. The aim of our study was to evaluate the expression of selected suppressor genes (ATM, BRCA1, BRCA2), proto-oncogenes (KRAS, c-JUN, c-FOS), pro-apoptotic genes (NOXA, PUMA), genes related to chromatin remodeling (MEN1), and genes related to carcinogenesis (NOD2, CHEK2, EGFR). Tissue samples from 30 normal ovaries and 60 ovarian carcinoma tumors were provided for analysis of the gene and protein expression. Gene expression analysis was performed using the real-time PCR method. The protein concentrations from tissue homogenates were determined using the ELISA technique according to the manufacturers' protocols. An increase in the expression level of mRNA and protein in women with ovarian cancer was observed for KRAS, c-FOS, PUMA, and EGFR. No significant changes in the transcriptional levels we observed for BRCA1, BRCA2, NOD2, or CHEK2. In conclusion, we suggest that KRAS, NOXA, PUMA, c-FOS, and c-JUN may be associated with poor prognosis in ovarian cancer.
卵巢癌是全球女性死亡的常见原因。目前可用于治疗卵巢癌的诊断和预后程序要么不具有特异性，要么非常昂贵。基因表达谱分析已被证明是探索卵巢癌患者新分子标志物的一种非常有效的工具，尽管这些标志物与患者生存率和临床结果之间的联系仍然难以捉摸。我们正在寻找可能在卵巢癌发生发展过程中发挥作用的基因。我们研究的目的是评估选定的抑癌基因（ATM、BRCA1、BRCA2）、原癌基因（KRAS、c-JUN、c-FOS）、促凋亡基因（NOXA、PUMA）、与染色质重塑相关的基因（MEN1）以及与致癌作用相关的基因（NOD2、CHEK2、EGFR）的表达。提供了30个正常卵巢组织样本和60个卵巢癌肿瘤组织样本用于基因和蛋白质表达分析。基因表达分析采用实时PCR方法进行。根据制造商的方案，使用ELISA技术测定组织匀浆中的蛋白质浓度。在卵巢癌女性中，观察到KRAS、c-FOS、PUMA和EGFR的mRNA和蛋白质表达水平升高。我们未观察到BRCA1、BRCA2、NOD2或CHEK2转录水平有显著变化。总之，我们认为KRAS、NOXA、PUMA、c-FOS和c-JUN可能与卵巢癌的不良预后相关。
